<SEC-DOCUMENT>0001213900-23-017913.txt : 20230307
<SEC-HEADER>0001213900-23-017913.hdr.sgml : 20230307
<ACCEPTANCE-DATETIME>20230307060212
ACCESSION NUMBER:		0001213900-23-017913
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230307
FILED AS OF DATE:		20230307
DATE AS OF CHANGE:		20230307

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041
		FILM NUMBER:		23710935

	BUSINESS ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-6103100

	MAIL ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SciSparc Ltd./ADR
		DATE OF NAME CHANGE:	20210129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea174712-6k_scisparcltd.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer<BR>
Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of March 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-38041</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCISPARC LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>20 Raul Wallenberg Street, Tower A,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Tel Aviv 6971916 Israel</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F &#9746; Form 40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 6, 2023, SciSparc
Ltd. (the &ldquo;Company&rdquo;) issued a press release titled &ldquo;SciSparc Successfully Completed Production of its Proprietary Drug
Candidate SCI-110 for its Upcoming Clinical Trial on Tourette Syndrome.&rdquo; A copy of this press release is furnished herewith as Exhibit
99.1 and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first five paragraphs
and the section titled &ldquo;Forward-Looking Statements&rdquo; in the press release attached hereto as Exhibit 99.1 are incorporated
by reference into the registration statements on Form F-3 (File No. <U><A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390023012516/ea172999-f3_scisparc.htm">333-269839</A></U>, File No. <U><A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390022037966/ea162219-f3_scisparcltd.htm">333-266047</A></U>, File No. <U><A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390019016523/ff32019_therapixbio.htm">333-233417</A></U>
and File No. <U><A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390022022376/ea158932-posam_scisparcltd.htm">333-248670</A></U>) and on Form S-8 (File No. <U><A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390018008005/fs82018_therapixbiosciences.htm">333-225773</A></U>) filed with the Securities and Exchange Commission to be a
part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed
or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT INDEX</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea174712ex99-1_scisparcltd.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued by
    SciSparc Ltd. on March 6, 2023 titled &ldquo;SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110
    for its Upcoming Clinical Trial on Tourette Syndrome.&rdquo;</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SciSparc Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 7, 2023</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Oz Adler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and<BR>
Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea174712ex99-1_scisparcltd.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY SCISPARC LTD. ON MARCH 6, 2023 TITLED "SCISPARC SUCCESSFULLY COMPLETED PRODUCTION OF ITS PROPRIETARY DRUG CANDIDATE SCI-110 FOR ITS UPCOMING CLINICAL TRIAL ON TOURETTE SYNDROME."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B><IMG SRC="image_001.jpg" ALT="" STYLE="height: 296px; width: 296px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 12pt"><B>SciSparc
Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome</B></FONT></P>

<P STYLE="text-align: justify; font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Your publication date and time will appear
here.| Source:<B>SciSparc Ltd</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">TEL AVIV, Israel, March 06, 2023 (GLOBE NEWSWIRE)
-- SciSparc Ltd. (Nasdaq: SPRC) (the &ldquo;Company&rdquo; or &ldquo;SciSparc&rdquo;), a specialty, clinical-stage pharmaceutical company
focusing on the development of therapies to treat disorders of the central nervous system, today announced that it has successfully manufactured
clinical batches of its top-tier drug candidate SCI-110 to be used in its upcoming multinational, multicenter, Phase IIb trial for Tourette
Syndrome (&ldquo;TS&rdquo;).&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">SCI-110 batches were manufactured by Procaps
Group S.A. (&ldquo;Procaps&rdquo;), a global leader in contract development and manufacturing services and in soft-gel advanced technologies
for the global pharmaceutical industry, and under Good Manufacturing Process conditions to comply with the U.S. Food and Drug Administration
(the &ldquo;FDA&rdquo;), the European Medicines Agency and Israeli Ministry of Health rigorous requirements.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Company has already received ethics committee
approvals from the Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel. The Company
is currently preparing to submit a request for approval to the Institutional Review Board of Yale University, Connecticut, USA (&ldquo;Yale&rsquo;s
IRB&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">TS is a movement and neurobehavioral disorder
characterized by chronic motor and vocal tics. With the onset before age 18, about half to two-thirds of TS cases improve during adolescence,
while adults are generally more severe patients. Tics may be associated with a premonitory sensation to perform a specific action, which
may lead to &ldquo;relief&rdquo; once performed.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The objective of this Phase IIb randomized,
multi-national, multi-center, double-blind, placebo controlled cross-over study is to evaluate the efficacy, safety and tolerability of
SciSparc&rsquo;s proprietary drug candidate SCI-110 in adult patients (between 18 and 65 years of age) using oral treatment daily. The patients
will be randomized in a 1:1 ratio to receive either SCI-110 or a SCI-110 matched placebo. The primary efficacy objective of the study
will be to assess tic severity change using the Yale Global Tic Severity Scale, the most commonly used measure in clinical trials, as
a continuous endpoint at week 12 and week 26 of the double-blind phase compared to baseline. The primary safety objective of the study
will be to assess absolute and relative frequencies of serious adverse events for the entire population and separately for the SCI-110
and placebo groups. The launch of the trial is subject to approvals by FDA, the German Federal Institute for Drugs and Medical Devices
, the Israeli &nbsp;Ministry of Health and Yale&rsquo;s IRB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;Today&rsquo;s announcement is the culmination
of a long period of efforts by the Procaps team focused on the development of a reliable manufacturing process to enable production of
SCI-110 in an innovative unigel platform&rdquo; said Oz Adler, Chief Executive Officer of SciSparc. &ldquo;With the successful manufacturing
of the clinical batches, we are one step closer to initiate this important clinical trial.&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About SciSparc Ltd. (NASDAQ: SPRC):</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">SciSparc Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc&rsquo;s focus is on creating and enhancing
a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the
following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette syndrome,
for the treatment of Alzheimer&rsquo;s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum
disorder and status epilepticus.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-Looking Statements:</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This press release contains forward-looking
statements within the meaning of the &ldquo;safe harbor&rdquo; provisions of the Private Securities Litigation Reform Act of 1995 and other
Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses the design and objective of Phase
IIb clinical trial for treatment of TS and the pending further regulatory approvals in the United States, Germany and Israel. Historic
results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials
will suggest identical or even similar conclusions. Because such statements deal with future events and are based on SciSparc&rsquo;s current
expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ
materially from those described in or implied by the statements in this press release. The forward- looking statements contained or implied
in this press release are subject to other risks and uncertainties, including those discussed under the heading &ldquo;Risk Factors&rdquo;
in SciSparc&rsquo;s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on April 28, 2022,
and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update
or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future
events or circumstances or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B></B>IR@scisparc.com<BR>
Tel: +972-3-6167055</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $H 2@# 2(  A$! Q$!_\0
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MC9##V-2U\9>#?B7X@\%S*ME<F:QSE[28Y0_3^[^%?2W@?XFZ%XW@"6\OV;4
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M*WD>5T\N(DK\I]ZZV@ HHHH **** / OCI\.8%M7\6:3 L;(<7T2# 8'H_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR7<MU=H?N'U';:/UKTVN3\#>!-,\#:.+2R7S+F3FXN6'S2-_A[5UE !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !115:]O[73K9KB]N(K>!.6DE<*HH L$XI:\7\2_&Q[VZ;1
MO MA+J5^YVBY\LE![JO?ZGBO3_"[:RWANR.OI&NJ>7^_$9R,T :Y 92" 0>Q
M%9VDZ!I>A131Z78PVJS2&201+C<Q[UIT4  HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C-8/B[Q)'X
M3\-W.LRVLMRD&,QQG!Y.*\I7XO>.=?./#O@J0(WW9)%=Q^> * /=**\,3PY\
M8O%5S%)JNLQ:3;*X;RXWV]#G[J=?Q->W0JZ0QK(V]U4!F QD^M $G>O'-3^$
M>N^+/%5U<^)O$4LND)*?LT$1^8IV&.BU[)10!A>&_"6B>$[+[+H]A';@_>DQ
MEW_WFZFMVBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@!CQI*A21%93U##(IP4*,* !Z"BB@
C!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
